These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 20636954)

  • 1. The direct cost of intravenous insulin infusions to the NHS in England and Wales.
    Rajendran R; Scott A; Rayman G
    Clin Med (Lond); 2015 Aug; 15(4):330-3. PubMed ID: 26407380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin.
    Holden SE; Poole CD; Morgan CL; Currie CJ
    BMJ Open; 2011 Jan; 1(2):e000258. PubMed ID: 22021891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of cost on prescribing diabetes medications for older adults with type 2 diabetes in the outpatient setting.
    Lussier ME; Desai RJ; Wright EA; Gionfriddo MR
    Res Social Adm Pharm; 2024 Aug; 20(8):755-759. PubMed ID: 38697890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of insulin use and value for money in type 2 diabetes in the United kingdom.
    Gordon J; Evans M; McEwan P; Bain S; Vora J
    Diabetes Ther; 2013 Jun; 4(1):51-66. PubMed ID: 23296753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective analysis of NHS patient dental charges in England, Scotland and Wales.
    Chestnutt IG; Cope AL
    Br Dent J; 2024 Aug; ():. PubMed ID: 39152267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The type 1 diabetes grand challenge: The potential for transformative impact from the largest ever investment, £50 million and collaborative thinking across the UK.
    Robertson E; Sutcliffe J; Connor R; Heller SR
    Diabet Med; 2024 Jul; 41(7):e15376. PubMed ID: 38837491
    [No Abstract]   [Full Text] [Related]  

  • 7. Availability, affordability and price components of insulin products in different-level hospital pharmacies: Evidence from two cross-sectional surveys in Nanjing, China.
    Wang L; Dai L; Liu H; Dai H; Li X; Ge W
    PLoS One; 2021; 16(8):e0255742. PubMed ID: 34383816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment.
    Beran D; Ewen M; Lipska K; Hirsch IB; Yudkin JS
    Curr Diab Rep; 2018 Jun; 18(8):48. PubMed ID: 29907884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study.
    Eibich P; Green A; Hattersley AT; Jennison C; Lonergan M; Pearson ER; Gray AM
    Diabetes Ther; 2017 Oct; 8(5):1031-1045. PubMed ID: 28879529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China.
    Liu C; Zhang X; Liu C; Ewen M; Zhang Z; Liu G
    BMC Health Serv Res; 2017 Aug; 17(1):597. PubMed ID: 28836974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.
    Śliwczyński A; Brzozowska M; Jacyna A; Iltchev P; Iwańczuk T; Wierzba W; Marczak M; Orlewska K; Szymański P; Orlewska E
    PLoS One; 2017; 12(6):e0178764. PubMed ID: 28582404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.
    Currie CJ; Poole CD; Evans M; Peters JR; Morgan CL
    J Clin Endocrinol Metab; 2013 Feb; 98(2):668-77. PubMed ID: 23372169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The insulin dilemma in resource-limited countries. A way forward?
    Gill GV; Yudkin JS; Keen H; Beran D
    Diabetologia; 2011 Jan; 54(1):19-24. PubMed ID: 20835860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.
    Currie CJ; Peters JR; Evans M
    Diabet Med; 2010 Jul; 27(7):744-52. PubMed ID: 20636954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of primary care treatment costs and treatment efficacy for people with Type 1 and Type 2 diabetes in the United Kingdom from 1997 to 2007*.
    Currie CJ; Gale EA; Poole CD
    Diabet Med; 2010 Aug; 27(8):938-48. PubMed ID: 20653753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
    Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
    Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the future.
    Tucker DM; Palmer AJ
    Prim Care Diabetes; 2011 Apr; 5(1):9-17. PubMed ID: 21071296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.